Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 5:17 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 2,911 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Event Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Hypotension Prediction Index to Predict Epidural-labor Analgesia Induced Hypotension

NCT05906368
View directory record Official record
Conditions
Anesthesia, Epidural, Hypotension
Interventions
ClearSight HPI Monitoring system, Standard of Care Blood Pressure Monitoring
Diagnostic Test
Lead sponsor
Grace Lim, MD, MS
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Nov 3, 2026, 5:17 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult Participants

NCT06774313
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-142, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Nov 3, 2026, 5:17 AM EST
Completed No phase listed Observational

Usefulness of Cardiopulmonary Exercise Testing for Cardiovascular Risk Estimation and Frailty Assessment in Liver Transplant Candidates

NCT04543825
View directory record Official record
Conditions
Cardiovascular Diseases+Liver Transplantation
Interventions
Cardiopulmonary exercise testing
Device
Lead sponsor
Andres Duarte-Rojo
Other
Eligibility
45 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Phoenix, Arizona • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Nov 3, 2026, 5:17 AM EST
Completed Not applicable Interventional Results available

Long-term Monitoring of Patients With Cardiac Amyloidosis With Implantable Event Monitors

NCT04421040
View directory record Official record
Conditions
TTR Cardiac Amyloidosis
Interventions
Biotronik Biomonitor 3 implant of device, Biotronik Biomonitor 3 explant of device
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Nov 3, 2026, 5:17 AM EST
Completed Phase 2Phase 3 Interventional Results available

Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency

NCT01371825
View directory record Official record
Conditions
Lysosomal Acid Lipase Deficiency, Wolman Disease
Interventions
Sebelipase alfa (SBC-102)
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Up to 24 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Nov 3, 2026, 5:17 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Measuring Environmental Tobacco and Cannabis: Pollutants and Exposures

NCT06030674
View directory record Official record
Conditions
Healthy
Interventions
Secondhand cannabis emissions/smoke exposure
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 50 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Nov 3, 2026, 5:17 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Disparities in Late Life Depression and Metabolic Syndrome

NCT01428791
View directory record Official record
Conditions
Depressive Symptoms, Metabolic Syndrome X, Overweight, Obesity, Hypertension, Hyperglycemia, Dyslipidemias
Interventions
Generations older adult membership program, BRIGHTEN Heart Virtual Team intervention
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
60 Years to 110 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 23, 2022 · Synced Nov 3, 2026, 5:17 AM EST
Completed No phase listed Observational

Retrospective Assessment of AE-Related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

NCT05874817
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
17,517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Nov 3, 2026, 5:17 AM EST
Completed Phase 4 Interventional Results available

A Carotid Stenting Boston Scientific Surveillance Program

NCT00741091
View directory record Official record
Conditions
Carotid Artery Disease
Interventions
Carotid WALLSTENT Monorail Endoprosthesis, FilterWire EZ™ System™
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,097 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
112
States / cities
Birmingham, Alabama • Fairhope, Alabama • Phoenix, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2011 · Synced Nov 3, 2026, 5:17 AM EST
Completed Not applicable Interventional Results available

A Comparison of Non-invasive Ventilation Methods Used to Prevent Endotracheal Intubation Due to Apnea in Very Low Birth Weight Infants

NCT03298035
View directory record Official record
Conditions
Apnea of Prematurity
Interventions
NCPAP as mode for apnea prevention, NIPPV as rescue mode for apnea prevention
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Not listed
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Nov 3, 2026, 5:17 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Advanced MRI for Uteroplacental Flow, Perfusion, Oxygenation & Inflammation

NCT02791568
View directory record Official record
Conditions
Pregnancy, Obesity, Preeclampsia
Interventions
Ultrasound Scan, MRI Scan, Ferumoxytol
Procedure · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Nov 3, 2026, 5:17 AM EST
Completed Phase 1 Interventional

To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients

NCT00258050
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Midazolam, Lapatinib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Lebanon, New Hampshire • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Nov 3, 2026, 5:17 AM EST
Completed Phase 3 Interventional Results available

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

NCT02344290
View directory record Official record
Conditions
HIV, Cardiovascular Diseases
Interventions
Pitavastatin, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
40 Years to 75 Years
Enrollment
7,769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
91
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 59 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Nov 3, 2026, 5:17 AM EST
Terminated Phase 2 Interventional Results available

A Futility Trial of Sirolimus in Multiple System Atrophy

NCT03589976
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
Sirolimus 2 MG, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
30 Years to 80 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Nov 3, 2026, 5:17 AM EST
Active, not recruiting Phase 2 Interventional

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

NCT06120140
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Amivantamab IV, Amivantamab SC, Lazertinib, Doxycycline, Minocycline, Clindamycin, Chlorhexidine, Noncomedogenic skin moisturizer, Ruxolitinib, Tacrolimus, Zinc gluconate, Propranolol, Timolol, Clobetasol
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
28
States / cities
Chandler, Arizona • Duarte, California • Fullerton, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 3, 2026, 5:17 AM EST
Completed Not applicable Interventional

Integrating Sleep, Nightmare and PTSD Treatments

NCT02236390
View directory record Official record
Conditions
Nightmares, PTSD
Interventions
Exposure, Relaxation, and Rescripting Therapy, Cognitive Processing Therapy - Cognitive
Behavioral
Lead sponsor
University of Tulsa
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Nov 3, 2026, 5:17 AM EST
Completed Not applicable Interventional

Improved Patient Handoffs to Prevent Sentinel Events

NCT01855646
View directory record Official record
Conditions
Health Care Quality, Access and Evaluation
Interventions
Structured Sign Out Form
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
4,344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 25, 2016 · Synced Nov 3, 2026, 5:17 AM EST
Completed No phase listed Observational

Identification of Carotid Vasa Vasorum and Correlation With Acute Coronary Events

NCT01436773
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Nov 3, 2026, 5:17 AM EST
Recruiting Phase 3 Interventional

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

NCT05995353
View directory record Official record
Conditions
Crohn's Disease
Interventions
Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 17 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
11
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Oakland, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 3, 2026, 5:17 AM EST
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

NCT07059845
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Mirvetuximab Soravtansine, Bevacizumab, Carboplatin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
31
States / cities
La Jolla, California • Solvang, California • Gainesville, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 3, 2026, 5:17 AM EST
Completed Phase 1 Interventional Results available

Trial of ARV-110 and Abiraterone in Participants With Metastatic Prostate Cancer

NCT05177042
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
Bavdegalutamide, Abiraterone
Drug
Lead sponsor
Arvinas Androgen Receptor, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
9
States / cities
Santa Monica, California • New Haven, Connecticut • Fort Myers, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Nov 3, 2026, 5:17 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Cognitive Enhancement Through Model-based and Individualized Neurostimulation

NCT06235970
View directory record Official record
Conditions
Transcranial Electrical Stimulation (tES)
Interventions
Transcranial electrical stimulation (tES) including SHAM
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 45 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Nov 3, 2026, 5:17 AM EST
Completed Phase 2 Interventional Results available

Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC)

NCT00487669
View directory record Official record
Conditions
Advanced Non-small Cell Lung Cancer
Interventions
paclitaxel poliglumex, pemetrexed
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Nov 3, 2026, 5:17 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cerebral Oxygenation in Total Hip Arthroplasty Patients

NCT02325154
View directory record Official record
Conditions
Cerebral Oxygen Desaturation, Post-operative Delirium
Interventions
Cerebral Oximeter
Device
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Nov 3, 2026, 5:17 AM EST